Krystal Biotech: announces clinical data from Gorlin syndrome study

What happened

• Krystal Biotech, Inc. announced clinical data from its Gorlin Syndrome Pilot Study evaluating KB113 for the treatment of basal cell carcinomas in patients with Gorlin syndrome.
• The company issued a press release dated Oct 15, 2026 and said the data will be presented by study investigator Shireen V. Guide, MD in a poster entitled “Use of an HSV-1-Based Immunotherapy, KB113, to Treat Basal Cell Carcinoma in Patients with Gorlin Syndrome” at the 14th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, Oct 15–17, 2026 in Alexandria, Virginia.
• The press release and the poster are furnished as Exhibit 99.1 and Exhibit 99.2 to the Form 8-K and are available on the “Investors” section of the company website at www.krystalbio.com.

Key details

• Press release date: Oct 15, 2026.
• Conference: 14th PeDRA Annual Conference, Oct 15–17, 2026, Alexandria, Virginia.
• Poster presenter: Shireen V. Guide, MD; poster title uses the company wording and references KB113 and HSV-1-based immunotherapy.
• The report is signed on behalf of Krystal Biotech, Inc. by Krish S. Krishnan, Chairman and Chief Executive Officer, dated Oct 15, 2026.

Why it may matter

• The filing reports Item 7.01 (Regulation FD Disclosure), which covers public release of information such as the press release and poster furnished with the report.
• This filing does not show why the insider traded or why the company acted.